for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Novacyt SA

NCYT.L

Latest Trade

219.75GBp

Change

26.25(+13.57%)

Volume

3,851,148

Today's Range

199.40

 - 

227.66

52 Week Range

6.03

 - 

227.66

As of on the Euronext Paris ∙ Minimum 15 minute delay

Latest Developments

CNR Of Institut Pasteur Has Approved COVID-19 Test Of Novacyt

April 6 (Reuters) - Novacyt SA <ALNOV.PA>::COVID-19 DIAGNOSTIC REGULATORY UPDATE.CNR (CENTRE NATIONAL DE RÉFÉRENCE DES VIRUS DES INFECTIONS RESPIRATOIRES (DONT LA GRIPPE)) OF INSTITUT PASTEUR, HAS APPROVED ITS COVID-19 TEST.COMPANY'S CE-MARK TEST IS AVAILABLE FOR IMMEDIATE DISTRIBUTION INTO FRENCH MARKET.2 APRIL 2020, NOVACYT ALSO RECEIVED APPROVAL FOR ITS COVID-19 TEST FROM MINISTRY OF HEALTH IN THAILAND.

Novacyt Announces Approval Of Its COVID-19 Test In India And Argentina

March 30 (Reuters) - NOVACYT SA <ALNOV.PA>::CORONAVIRUS TEST UPDATE.COVID-19 TEST APPROVED IN INDIA AND ARGENTINA.COMPANY HAS COMMITTED TO PURCHASING ADDITIONAL RAW MATERIALS TO PRODUCE A TOTAL OF 18 MILLION COVID-19 TESTS.ON 27 MARCH 2020, NOVACYT RECEIVED APPROVAL FOR TEST FROM NATIONAL ADMINISTRATION OF DRUGS, FOODS AND MEDICAL DEVICES (ANMAT) IN ARGENTINA.COMPANY EXPECTS TO SIGN FURTHER DISTRIBUTION PARTNERSHIPS DURING NEXT FEW WEEKS IN THE MIDDLE-EAST.CONTINUES TO WORK WITH A GROWING NUMBER OF HOSPITALS IN UK AND IS NOW SUPPLYING MORE THAN 21 HOSPITALS ACROSS COUNTRY.EXPECTS TO UPDATE ON ITS PROGRESS IN US MARKET FOLLOWING EMERGENCY USE AUTHORIZATION GRANTED BY US FOOD AND DRUG ADMINISTRATION ANNOUNCED ON 23 MARCH 2020.COMPANY ALSO REPORTS THAT ITS COVID-19 TEST IS NOW BEING USED BY HEALTH SERVICE EXECUTIVE IN IRELAND AND ORDERS FOR £1.1 MILLION (€1.2 MILLION) TESTS HAVE BEEN RECEIVED.DIRECTORS CAN CONFIRM THAT THIS LEVEL OF SALES WILL CONTRIBUTE SIGNIFICANTLY TO IMPROVED GROSS MARGIN AND PROFITABILITY FOR GROUP.NOVACYT CAN CONFIRM ITS MANUFACTURING PARTNER, LOCATED IN MAINLAND EUROPE, IS BIOTYPE DIAGNOSTIC GMBH (BIOTYPE).

Novacyt Signs Global Distribution Agreement With Bruker For Covid-19 Diagnostic Test

March 25 (Reuters) - NOVACYT SA <ALNOV.PA>::GLOBAL DISTRIBUTION AGREEMENT WITH BRUKER FOR COVID-19 DIAGNOSTIC TEST.ANNOUNCES THAT REPUBLIC OF PHILIPPINES DEPARTMENT OF HEALTH FOOD AND DRUG ADMINISTRATION HAS APPROVED COMPANY'S COVID-19 TEST FOR COMMERCIAL USE, EFFECTIVE IMMEDIATELY.BRUKER HAS ALREADY INITIATED SHIPMENTS OF PRIMERDESIGN TEST INTO SPAIN, FRANCE, GERMANY AND UK..

Novacyt Signs Agreement With Yourgene Health To Support Demand For COVID-19 Tests

March 25 (Reuters) - NOVACYT SA <ALNOV.PA>::CONTRACT MANUFACTURING SERVICES AGREEMENT SIGNED WITH YOURGENE HEALTH PLC.ADDITIONAL MANUFACTURING CAPACITY TO SUPPORT DEMAND FOR NOVACYT'S COVID-19 DIAGNOSTIC TEST.FIRST BATCHES OF CRITICAL COMPONENTS ARE EXPECTED TO BE SHIPPED FROM CITYLABS SITE TO PRIMERDESIGN IN SOUTHAMPTON, UK, OVER NEXT FEW WEEKS.TO EXPEDITE PROCESS, YOURGENE WILL INITIALLY MANUFACTURE CRITICAL COMPONENTS OF COVID-19 TEST.AGREEMENT FOR CERTAIN CONTRACT MANUFACTURING SERVICES WITH YOURGENE HEALTH PLC ("YOURGENE") (AIM: YGEN), AN INTERNATIONAL MOLECULAR DIAGNOSTICS GROUP..TWO COMPANIES MAY SEEK TO EXPAND AGREEMENT TO INCLUDE PRODUCTION OF FINAL VERSIONS OF COVID-19 TEST IN DUE COURS.YOURGENE WILL SUPPORT NOVACYT IN PRODUCTION OF COVID-19 DIAGNOSTIC TEST DEVELOPED BY PRIMERDESIGN, COMPANY'S MOLECULAR DIAGNOSTICS DIVISION.YOURGENE'S GMP (GOOD MANUFACTURING PRACTICE) STATE-OF--ART MANUFACTURING FACILITY AT CITYLABS IN MANCHESTER, UK, WILL BE USED TO EXPAND NOVACYT'S PRODUCTION CAPACITY OF COVID-19 TEST..YOURGENE WILL INITIALLY MANUFACTURE CRITICAL COMPONENTS OF COVID-19 TEST.FIRST BATCHES OF CRITICAL COMPONENTS ARE EXPECTED TO BE SHIPPED FROM CITYLABS SITE TO PRIMERDESIGN IN SOUTHAMPTON, UK, OVER NEXT FEW WEEKS..

Bruker Announces Launch Of CE-Ivd Marked Genesig Assay Kit For Detection Of Sars-Cov-2 Virus

March 24 (Reuters) - Bruker Corp <BRKR.O>::BRUKER ANNOUNCES LAUNCH OF CE-IVD MARKED GENESIG® ASSAY KIT FOR THE DETECTION OF THE SARS-COV-2 VIRUS.BRUKER - AGREEMENT WITH PRIMER DESIGN, PART OF NOVACYT GROUP, FOR BRUKER-HAIN DIAGNOSTICS DISTRIBUTION OF GENESIG COVID-19 DIAGNOSTICS KITS.

Novacyt To Increase Manufacturing Capacity In Face Of Increasing Demand For COVID-19 Tests

March 20 (Reuters) - NOVACYT SA <ALNOV.PA>::CORONAVIRUS TEST UPDATE: SIGNIFICANT INCREASE IN DEMAND, FURTHER EXPANSION OF MANUFACTURING CAPACITY.AS OF TODAY, PRIMERDESIGN HAS SOLD AND RECEIVED ORDERS FOR OVER £8.7 MILLION (EUR 9.6 MILLION) OF ITS CE-MARK AND RESEARCH USE ONLY (RUO) COVID-19 TESTS.ALL NOVACYT STAFF AND COMPANY'S RECENTLY APPOINTED MANUFACTURING PARTNER ARE WORKING AT FULL CAPACITY TO FULFIL THIS DEMAND.THIS REPRESENTS AROUND 18 MONTHS OF TOTAL SALES FOR DIVISION UNDER NORMAL CIRCUMSTANCES AND ALREADY EXCEEDS TOTAL SALES ACHIEVED BY PRIMERDESIGN IN 2019.COMPANY CONFIRMS IT IS TAKING FURTHER ACTION TO INCREASE ITS MANUFACTURING CAPACITY.HAS PURCHASED ADDITIONAL RAW MATERIALS SO THAT IT IS NOW ABLE TO PRODUCE MORE THAN 5 MILLION COVID-19 TESTS AND WILL CONSTANTLY REVIEW THIS DURING NEXT FEW WEEKS.ANNOUNCES IT IS IN ADVANCED DISCUSSIONS WITH A SECOND THIRD-PARTY MANUFACTURER, BASED IN THE UK, IN ORDER TO FURTHER EXPAND MANUFACTURING CAPACITY.HAVING THREE INDEPENDENT MANUFACTURING SITES ALSO ENABLES COMPANY TO DE-RISK ITS OWN SUPPLY CHAIN IN EVENT THAT COVID-19 DISRUPTS MANUFACTURING OPERATIONS.

Novacyt Expects Increase In Number Of NHS Hospitals Purchasing Primerdesign's COVID-19 Test

March 12 (Reuters) - Novacyt SA <ALNOV.PA>::CORONAVIRUS TEST UPDATE.HAS INVESTED IN A SIGNIFICANT INCREASE IN MANUFACTURING CAPACITY TO SUPPORT GROWING DEMAND FOR ITS COVID-19 TEST..PRIMERDESIGN SOLD AND RECEIVED ORDERS FOR OVER £2.3 MILLION (EUR 2.6 MILLION) OF ITS CE-MARK AND RESEARCH USE ONLY (RUO) COVID-19 TESTS.COMPANY CANNOT PREDICT SALES WITH ANY CERTAINTY AS PIPELINE CONTINUES TO CHANGE DAILY.REPORTS COMPLETION OF A FORMAL EVALUATION OF ITS COVID-19 TEST BY PUBLIC HEALTH ENGLAND (PHE) AND IS VERY SATISFIED WITH PERFORMANCE ASSESSMENT OF ITS TEST.NOVACYT SA SAYS EXPECTS TO SEE AN INCREASE IN NUMBER OF NHS HOSPITALS PURCHASING PRIMERDESIGN'S COVID-19 TEST.

Novacyt Issues 6.4 Million New Ordinary Shares

Feb 19 (Reuters) - Novacyt SA <ALNOV.PA>::ANNOUNCES THAT IT HAS ISSUED TOTAL OF 6,370,728 NEW ORDINARY SHARES OF EUR 1/15 EACH IN CAPITAL OF COMPANY ("ORDINARY SHARES") PURSUANT TO EXERCISE OF WARRANTS.6,017,192 NEW ORDINARY SHARES HAVE BEEN ISSUED TO HARBERT EUROPEAN GROWTH CAPITAL FUND II AT A PRICE OF EUR 0.0698 PER SHARE FOR A TOTAL SUBSCRIPTION OF EUR 420,000.353,536 NEW ORDINARY SHARES ISSUED TO KREOS CAPITAL V (EXPERT FUND) L.P. AT A PRICE OF EUR 1.45 PER SHARE FOR TOTAL SUBSCRIPTION OF EUR 512,627.COMPANY HAS RECEIVED SUBSCRIPTIONS TOTALLING EUR 2.9M SINCE 31 JANUARY 2020.ADMISSION OF NEW ORDINARY SHARES TO TRADING ON EURONEXT IS EXPECTED ON OR BEFORE 25 FEBRUARY 2020.COMPANY ALSO ANNOUNCES THAT IT WILL MAKE NET PAYMENT OF EUR 158K TO NEGMA LIMITED IN ORDER TO SATISFY TERMS OF GUARANTEE PROVIDED TO NEGMA RELATING TO CANCELLATION OF 1,300,000 WARRANTS HELD BY NEGMA, AS ANNOUNCED ON 6 NOV 2019.

Novacyt Announces Exercise Of Warrants And Issue Of Equity

Feb 19 (Reuters) - Novacyt SA <ALNOV.PA>::EXERCISE OF WARRANTS AND ISSUE OF EQUITY.ADMISSION OF NEW ORDINARY SHARES TO TRADING ON EURONEXT IS EXPECTED TO OCCUR ON OR BEFORE 24 FEBRUARY 2020..HAS RECEIVED NOTICE FROM YA II CD, LTD OF EXERCISE OF WARRANTS TO SUBSCRIBE FOR 300,000 NEW ORDINARY SHARES OF EUR 1/15 EACH IN CAPITAL OF COMPANY AT PRICE OF EUR 0.946 PER SHARE FOR TOTAL SUBSCRIPTION OF EUR 283,800.FOLLOWING ADMISSION, TOTAL NUMBER OF SHARES IN COMPANY IS 61,302,839.PRICE OF EUR 0.946 PER SHARE.TOTAL SUBSCRIPTION OF EUR 283,800.

Novacyt - Exercise of Warrants and Issue of Equity

Feb 18 (Reuters) - Novacyt SA <ALNOV.PA>::ANNOUNCES IT RECEIVED NOTICE FROM ACCENT GRAVE BV OF EXERCISE OF WARRANTS TO SUBSCRIBE FOR 1,000,000 NEW ORDINARY SHARES OF EUR 1/15 EACH IN CAPITAL OF COMPANY.APPLICATION WILL BE MADE FOR 1,000,000 NEW ORDINARY SHARES TO BE ADMITTED TO TRADING ON AIM AND IT IS EXPECTED THAT ADMISSION WILL BECOME EFFECTIVE AT 8.00 A.M. ON OR AROUND 24 FEB 2020.FOLLOWING ADMISSION, TOTAL NUMBER OF SHARES IN COMPANY IS 61,002,839.AT A PRICE OF EUR 1.16 PER SHARE FOR A TOTAL SUBSCRIPTION OF EUR 1,160,000.ADMISSION OF NEW ORDINARY SHARES TO TRADING ON EURONEXT IS EXPECTED TO OCCUR ON OR BEFORE 24 FEBRUARY 2020.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up